METHODS We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B). Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran. Background Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |